Free Trial

STERIS logo with Medical background

Key Points

  • STERIS has been upgraded by Wall Street Zen from a "buy" rating to a "strong-buy" rating, indicating increased confidence in the stock's potential.
  • Morgan Stanley raised its target price for STERIS from $276.00 to $295.00 and maintained an "overweight" rating, reflecting bullish sentiment from multiple brokerages.
  • The company reported earnings of $2.34 per share, exceeding analyst expectations and showcasing an 8.8% year-over-year revenue increase to $1.40 billion.
  • MarketBeat previews the top five stocks to own by October 1st.
Like this article? Share it with a colleague.